STEMI patients who are found to be COVID-19-positive frequently do not have obstructed arteries identified during coronary angiography, according to a case series from the Lombardy region of Italy, ...
A new analysis of Medicare data raises additional questions about which patients with STEMI require management within an intensive care unit (ICU), a practice currently used for most such patients in ...
A newly published analysis in the Journal of the American College of Cardiology of hospitalized patients with both a severe type of heart attack called STEMI (ST-elevation myocardial infarction) and ...
Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with STEMI, a COVID-19 diagnosis significantly increased the rates of in-hospital ...
For patients with COVID-19 and STEMI, percutaneous coronary intervention remains the treatment of choice. For patients with COVID-19 and NSTEMI, conservative therapy is reasonable in hemodynamically ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with COVID-19 who present with ST-segment elevation MI represent a unique, high-risk ...
The benefits of complete revascularization over culprit-only coronary artery revascularisation were confirmed in older patients with ST-segment elevation myocardial infarction (STEMI) and multivessel ...
The STEMI DTU RCT plans to enroll 668 patients undergoing treatment for a STEMI heart attack at up to 60 sites. The study will have two arms. Half the patients will be randomized to receive 30 minutes ...
A trip to an intensive care unit can be more than twice as costly as a stay in a non-ICU hospital room, but a new study finds intensive care is still the right option for some vulnerable patients ...
Please provide your email address to receive an email when new articles are posted on . Risk factors for patients with acute MI have changed modestly as treatment has improved, with mortality rates ...
Mineralocorticoid-receptor antagonists (MRAs) have been shown to reduce adverse cardiovascular outcomes in high-risk patients with ST-segment elevation myocardial infarction (STEMI). Preliminary data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback